We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. If you would like to know more please click here.

Meet the team

Matt Tozer (Head of Medicinal Chemistry)

Matt is a graduate (BSc, 1986 and PhD) of Imperial College. He undertook post-doctoral research at the Australian National University and the University of Oxford. Embarking on a career in medicinal chemistry, he worked as a Staff Scientist at the James Black Foundation. He was Director of Medicinal Chemistry in the UK for the Anglo-Swedish biotech Medivir. He was Director of Peakdale Chemistry Services and Head of Site for Peakdale's operation in Sandwich, leading Peakdale's pioneering embedded unit with Pfizer and then as one of the first tenants on Discovery Park. As Peakdale's Director of Medicinal Chemistry Services, he had a substantial role in the leadership team for the wider company. He held a similar leadership role as Chief Scientific Officer at AlgaeCytes. He now leads medicinal chemistry at Cyclofluidic. He is also a scientific consultant, supporting medicinal chemistry programmes and facilitating industrial-academic collaborations. He is an active and dedicated contributor to the Royal Society of Chemistry, notably through the Biological and Medicinal Chemistry Sector and the Organic Division. He is also an elected member of the Executive Committee of the European Federation for Medicinal Chemistry.

Adrian Wright (Head of Analytical Chemistry)

Adrian provides the analytical expertise to the project. He completed his degree in Medicinal and Pharmaceutical Chemistry at Loughborough University before going on to complete a PhD in Computer-aided Optimisation of Liquid Chromatography at University of Bradford. He subsequently worked for GSK in Analytical Development for 3 years before moving to Pfizer to create a Separation Sciences group to support Chemistry research. Over 20 years his group grew to 14 scientists offering analysis, purification and auto-purification to 120 chemists. Despite managing a large group and having significant supervisory responsibilities, he maintained a strong hands-on practical role. Adrian was heavily involved in introducing new technologies and the innovative use of existing approaches. One of his strengths is the use of automation and the development of integrated systems to provide high throughput, fast turn round services. He introduced comprehensive, automated screening for chromatographic method development and, later, extended it to 4-channel parallel operation for chiral separations. After recognising the problems associated with screening of impure samples, he developed and introduced auto-purification approaches to chemical library synthesis. A total of three generations of auto-purification system were devised and implemented; the first two before manufacturers develop instrumentation aimed at this area. The third generation was adopted worldwide within Pfizer and was the purification system for all small scale output from Chemical Research , not just library synthesis. Each generation was able to process hundreds of samples with short turn-round. The second generation holds the record at 50,000 compounds purified in a 6 month period. The advancing generations reduce turn-round times, provided more information on the samples and provided outputs that seamlessly integrated into the hit discovery process. Adrian also pioneered the use of ELSD for quantitation in automated systems and developed two novel approaches able to provide concentration information, without standards, in real time. After leaving Pfizer he applied his technical knowledge at Cyclofluidic to help build, refine and extend the CyclOps platforms. He has a proven track record of delivering solutions to technical problems and the skill set to ensure the objectives of the project are met.

Manoj Ramjee (Head of Biology)

Manoj completed his DPhil. SERC-ICE CASE award with Dr Roger Thorneley (University of Sussex), Dr Tim Hawkes (ICI Agrochemicals) and Prof John Coggins (University of Glasgow) in molecular enzymology based at the University of Sussex followed by a Fulbright Scholarship with Prof Jack Kirsch at the University of California, Berkeley. He returned to the UK to take up a Research Associate position at University of Cambridge in the laboratories of Prof Chris Abell and Prof Alison Smith. Following this, he joined Peptide Therapeutics (Acambis) as a Research Scientist eventually becoming Director of Biological Chemistry. In 2001 he was one of the scientific founders of Incenta, which raised venture capital funding to exemplify novel IP and eventually became Chief Operating Officer of the Amura Therapeutics (acquired Incenta Limited). In 2009 he set up his own consultancy business and thereafter became Head of Biology at Cyclofluidic. Manoj has significant background and experience in assay technologies, small molecule compound screening and pre-clinical drug discovery in a number of therapeutic areas. He is an expert in assay technologies applied to drug discovery, particularly hardware and automation. He has developed over one hundred assays during his career and is an inventor on a number of patents. In his role at Cyclofluidic Limited he has had technical oversight of over thirty client projects encompassing initial technical feasibility, assay transfer and optimisation, deployment and data generation.